Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 50 of 65 publications.

Melen E, Faner R, Allinson JP, Bui D, Bush A, Custovic A, Garcia-Aymerich J, Guerra S, Breyer-Kohansal R, Hallberg J, Lahousse L, Martinez FD, Merid SK, Powell P, Pinnock H, Stanojevic S, Vanfleteren LEGW, Wang G, Dharmage SC, Wedzicha J, Agusti Alvar, Abellan A, CADSET Investigators. Lung-function trajectories: relevance and implementation in clinical practice. Lancet. 2024 Apr 13;403(10435):1494-503. doi: 10.1016/S0140-6736(24)00016-3

Sweeney C, Gilsenan A, Calingaert B, Moeller C, Schomakers G, Sok A, Holzmann R, Pisa F. Physician awareness of the safe use of cyproterone acetate in Europe: a survey on the effectiveness of additional risk minimization measures. Pharmaceut Med. 2024 Mar;38(2):145-56. doi: 10.1007/s40290-023-00510-x.

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Michel A, Latocha M, Schmidt-Ott UM, Lovic N, Brunck LR, Johnson KT, Suzart-Woischnik K. Evaluation of physician knowledge of safety and safe use information for intravitreal aflibercept injection in Europe: a second survey of physicians following dissemination of updated risk-minimization materials. Pharmaceut Med. 2024 Jan;38(1):63-73. doi: 10.1007/s40290-023-00506-7

Ho KA, Pierce A, Stoltenberg M, Tarancon T, Mansfield C. Eliciting exploratory patient preference data: a case study in a rare disease. Pharmaceut Med. 2024 Jan;38(1):55-62. doi: 10.1007/s40290-023-00509-4.

Gibble TH, Sweeney C, Wolin D, McSorley D, Wang J, Koushik AK, Moses RE, Dubinsky MC. Real-world experience and perspectives on the treatment of crohn's disease: results from a healthcare provider survey. Poster presented at the 2023 Advances in Inflammatory Bowel Diseases (AIBD) Annual Meeting; December 14, 2023. Orlando, FL. [abstract] Am J Gastroenterol. 2023 Dec; 118(12S):S19.

Charabaty A, Gibble TH, Moses R, Sweeney C, Wolin D, McSorley D, Wang J, Rodriguez M, Park B, Dubinsky M. Assessing bowel urgency in clinical practice: results from a healthcare professional survey. Poster presented at the AJG 2023 Annual Scientific Meeting; October 24, 2023. Vancouver, Canada. [abstract] Am J Gastroenterol. 2023 Oct; 118(10S):S894-5. doi: 10.14309/01.ajg.0000954312.41350.0a

Reed SD, Zhou X, Ichikawa L, Gatz JL, Peipert JF, Armstrong MA, Raine-Bennett T, Getahun D, Fassett MJ, Postlethwaite DA, Shi JM, Asiimwe A, Pisa F, Schoendorf J, Saltus CW, Anthony MS, APEX-IUD study team. Intrauterine device-related uterine perforation incidence and risk (APEX-IUD): a large multisite cohort study. Lancet. 2022 Jun 4;399(10341):2103-12. doi: 10.1016/S0140-6736(22)00015-0

Gold BD, Goodwin B, Davis K, Sweeney C, Ziemiecki R, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Patient satisfaction and adherence to corticosteroids in adolescents and adults with eosinophilic esophagitis in a real-world setting in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S177.

Gold BD, Goodwin B, Davis K, Sweeney C, Reynolds M, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Health-related quality of life in adolescents and adults with eosinophilic esophagitis in a real world setting in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S176. doi: 10.14309/01.ajg.0000774068.59482.1e

Gold BD, Goodwin B, Davis K, Sweeney C, Garbinsky D, Jiang J, Fan T, Boules M, Desai NK, Katzka DA. Perceptions of disease stigma in adolescents and adults with eosinophilic esophagitis in the US. Poster presented at the 2021 Annual Scientific Meeting & Postgraduate Course (ACG); October 24, 2021. Las Vegas, NV. [abstract] Am J Gastroenterol. 2021 Oct; 116:S176-7. doi: 10.14309/01.ajg.0000774072.42679.92

Filippini T, Rothman KJ, Cocchio S, Narne E, Mantoan D, Saia M, Goffi A, Ferrari F, Maffeis G, Orsini N, Baldo V, Vinceti M. Associations between mortality from COVID-19 in two Italian regions and outdoor air pollution as assessed through tropospheric nitrogen dioxide. Sci Total Environ. 2021 Mar 15;760:143355. doi: 10.1016/j.scitotenv.2020.143355

Filippini T, Rothman KJ, Goffi A, Ferrari F, Maffeis G, Orsini N, Vinceti M. Satellite-detected tropospheric nitrogen dioxide and spread of SARS-CoV-2 infection in Northern Italy. Sci Total Environ. 2020 Oct 15;739:140278. doi: 10.1016/j.scitotenv.2020.140278

Osorio-Yanez C, Clemente DBP, Maitre L, Vives-Usano M, Bustamante M, Martinez D, Casas M, Alexander J, Thomsen C, Chatzi L, Gutzkow KB, Grazuleviciene R, Martens DS, Plusquin M, Slama R, McEachan RC, Wright J, Yang TC, Urquiza J, Tamayo I, Sunyer J, Vafeiadi M, Nawrot TS, Vrijheid M. Early life tobacco exposure and children's telomere length: the HELIX project. Sci Total Environ. 2020 Apr;711:135028. doi: 10.1016/j.scitotenv.2019.135028

Jacquot E, Collin E, Ladner A, Tormos A, Hamm L, Perez-Gutthann S, Gutierrez L, Chirila C, Deltour N. Agomelatine drug utilisation study in selected European countries: a multinational, observational study to assess effectiveness of risk-minimisation measures. Pharmaceut Med. 2019 Aug;33(4):311-9. doi: 10.1007/s40290-019-00291-2

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport EK, Hollis KA, Schmidt-Ott UM, Petraro P, Vassilev ZP. Physician and patient knowledge of safety and safe use information for aflibercept in Europe: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):219-33. doi: 10.1007/s40290-019-00279-y

Zografos LJ, Andrews E, Wolin DL, Calingaert B, Davenport E, Hollis KA, Djokanovic N, Racanelli VS, Petraro P, Vassilev ZP. Evaluation of physician knowledge of the key safety information for aflibercept in Canada: evaluation of risk-minimization measures. Pharmaceut Med. 2019 Jun;33(3):235-46. doi: 10.1007/s40290-019-00278-z

Davis KH, Asiimwe A, Zografos LJ, McSorley DJ, Andrews EB. Evaluation of risk-minimization activities for cyproterone acetate 2 mg/ethinylestradiol 35 μg: a cross-sectional physician survey. Pharmaceut Med. 2017 Oct;31(5):339-51. doi: 10.1007/s40290-017-0203-9

GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, Gold A. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017 Sep 16;390(10100):P1211-59. doi: 10.1016/S0140-6736(17)32154-2

GBD 2016 Causes of Death Collaborators, Gold A. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017 Sep 16;390(10100):1151-210. doi: 10.1016/S0140-6736(17)32152-9

GBD 2015 Tobacco Collaborators, Gold A. Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the global burden of disease study 2015. Lancet. 2017 May 13;389(10082):1885-906. doi: 10.1016/S0140-6736(17)30819-X

Cechova E, Scheringer M, Seifertova M, Mikes O, Kroupova K, Kuta J, Forns J, Eggesbo M, Quaak I, de Cock M, van de Bor M, Patayova H, Palkovicova Murinova L, Kocan A. Developmental neurotoxicants in human milk: comparison of levels and intakes in three European countries. Sci Total Environ. 2017 Feb 1;579:637-45. doi: 10.1016/j.scitotenv.2016.11.046

Rubinat E, Marsal JR, Vidal T, Cebrian C, Falguera M, Vilanova MB, Betriu A, Fernandez E, Franch J, Mauricio D. Subclinical carotid atherosclerosis in asymptomatic subjects with type 2 diabetes mellitus. J Cardiovasc Nurs. 2016 Mar;31(2):E1-7. doi: 10.1097/JCN.0000000000000236

Fine P, Victora CG, Rothman KJ, Moore PS, Chang Y, Curtis V, Heymann DL, Slutkin G, May RM, Patel V, Roberts I, Wortley R, Torgerson C, Deaton A. John Snow's legacy: epidemiology without borders. Lancet. 2013 Apr 1;381(9874):1302-11.

Forns J, Torrent M, Garcia-Esteban R, Grellier J, Gascon M, Julvez J, Guxens M, Grimalt JO, Sunyer J. Prenatal exposure to polychlorinated biphenyls and child neuropsychological development: an anaylsis per each congener and specific cognitive domain. Sci Total Environ. 2012 Aug 15;432:338-43. doi: 10.1016/j.scitotenv.2012.06.012

Forns J, Torrent M, Garcia-Esteban R, Grellier J, Gascon M, Julvez J, Guxens M, Grimalt JO, Sunyer J. Prenatal exposure to polychlorinated biphenyls and child neuropsychological development in 4-year-olds: an analysis per congener and specific cognitive domain. Sci Total Environ. 2012 Aug 15;432:338-43. doi: 10.1016/j.scitotenv.2012.06.012

Yen L, Davis K, Longstreth G, Streck P, Hodgkins P. Resource utilization and health care costs associated with diverticulitis: results from a retrospective claims database analysis. Am J Gastroenterol. 2010 Oct 1;105(Suppl. 1):S431.

Nicandro JP, Tennis P, Bennett L, Hollis K, Shin P, Chuang E, Andrews E. Disability or restriction of daily activities is the most common indicator of disease severity in female patients with severe IBS-D: an analysis of the alosetron patient survey. Poster presented at the 2010 American College of Gastroenterology (ACG) Annual Scientific Meeting; October 2010. San Antonio, TX. [abstract] Am J Gastroenterol. 2010 Oct; 105(Suppl. 1):S410.

Carson R, Williams V, Nelson L, MacDougall J, Johnston J. Psychometric evaluation of patient-reported outcome measures for assessing IBS-c symptom severity and global change: results from a phase 2b study of linaclotide. Am J Gastroenterol. 2009 Oct 1;104:1113.

Parijs BAV, Price M, Leon F, Fehnel S. Relevance of the gastrointestinal symptom rating scale (GSRS) in patients with celiac disease. Poster presented at the American College of Gastroenterology 2008 Annual Scientific Meeting and Postgraduate Course; October 2008. Orlando, FL. [abstract] Am J Gastroenterol. 2008 Sep 1; 103(Suppl. S):S395.

Earnshaw SR, McDade CL, Mangel AW, Baran RW. Cost-effectiveness of lubiprostone in a managed care population with chronic idiopathic constipation. Poster presented at the 2007 ACG Annual Meeting; September 2007. [abstract] Am J Gastroenterol. 2007 Sep; 102(S2):S449-50.

Mangel AW, Fehnel SE. Adequate relief in IBS treatment trials: corrections to errors stated by Whitehead et al. Am J Gastroenterol. 2006 Dec;101(12):2884-5.

Chang L, Ameen VZ, Dukes GE, McSorley DJ, Carter EG, Mayer EA. A dose-ranging, phase II study of the efficacy and safety of alosetron in men with diarrhea-predominant IBS. Am J Gastroenterol. 2004;99:1-9.

Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Most bothersome symptoms in irritable bowel syndrome (IBS) patients. Am J Gastroenterol. 2004;99(10):842.

Northcutt AR, Perschy TL, Ameen VZ, Hamedani AG, McSorley DJ, Carter EG. Correlating global outcome measures in Irritable Bowel Syndrome (IBS). Am J Gastroenterol. 2004;99(10):843.

Humphries SE, Hawe E, Dhamrait S, Miller GJ, Talmud PJ. In search of genetic precision. Lancet. 2003;361(9372):1908-1909.

Rothman KJ. Cellular telephones and risk of brain tumours. Lancet. 2001 Mar 24;357(9260):961.

Wolfe SG, Chey WY, Washington MK, Harding J, Heath AT, McSorley DJ, Dukes GE, Hunt CM. Tolerability and safety of alosetron during long-term administration in female and male irritable bowel syndrome patients. Am J Gastroenterol. 2001 Mar;96(3):803-11.

Rothman KJ. Sizing up research. Lancet. 2001 Jan 1;357(9259):890.

Rothman KJ. Cellular telephones and risk of brain tumours - Reply. Lancet. 2001 Jan 1;357(9260):961.

Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GJ. Apolipoprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet. 2001;358(9276):115-9.

Rothman KJ. Epidemiological evidence on health risks of cellular telephones. Lancet. 2000 Nov;356(9244):1837-40.

Kogevinas M, Zock JP, Jarvis D, Kromhout H, Lillienberg L, Plana E. Exposure to substances in the workplace and new-onset asthma: an international prospective population-based study (ECRHS-II). Lancet. 2000 Jul 28;370(9584):336-41.

Schwartz HI, Perschy TB, McSorley DJ, Sorrells SC. Twice-daily versus thrice-daily clarithromycin in combination with ranitidine bismuth citrate in the eradication of Helicobacter pylori. Am J Gastroenterol. 1999 Jun;4(2):121-7.

Rothman KJ, Johnson ES, Sugano DS. Is flutamide effective in patients with bilateral orchiectomy? Lancet. 1999 Apr 3;353(9159):1184. doi: 10.1016/S0140-6736(05)74403-2

Mangel AW, Camilleri M, Chey WY, Hamm LR, Harding JP, Lawler C, McSorley DJ. Treatment of female IBS patients with alosetron, a potent and selective 5HT3-receptor antagonist. Am J Gastroenterol. 1999;116:G4505.

Mangel AW, Northcutt AR, Kong S, McSorley DJ. Validation of adequate relief as an endpoint in irritable bowel syndrome. Am J Gastroenterol. 1999;116:G4500.

Mangel AW, Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath AT, McSorley DJ. Alosetron, a 5-HT3 receptor antagonist, in the treatment of non-constipated female IBS patients. Am J Gastroenterol. 1999;94(9):2677.

Calvet X, Navarro M, Gil M, Lafont A, Sanfeliu I, Brullet E, Campo R, Dalmau B, Rivero E, Mas P. Epidemiology of peptic ulcer disease in cirrhotic patients: role of helicobacter pylori infection. Am J Gastroenterol. 1998 Dec;93(12):2501-7.

Jick H, Garcia Rodriguez LA, Perez-Gutthann S. Principles of epidemiological research on adverse and beneficial drug effects. Lancet. 1998 Nov 28;352(9142):1767-70.

Rothman KJ, Adami HO, Trichopoulos D. Should the mission of epidemiology include the eradication of poverty? Lancet. 1998 Sep 5;352(9130):810-3. doi: 10.1016/S0140-6736(98)01327-0